Oncology and Immuno-Oncology INSIGHTS


Webinar: Estrogen-Related Effects in Breast Cancer Xenograft Models

Breast cancer xenograft models are often treated with supplemental estrogen, but this can induce a range of adverse effects on immunodeficient mouse models including impaired urinary tract function and skin problems. Failure to control for these strain-dependent effects can seriously impact the reproducibility of preclinical research — or lead to early termination of your experiment due to their severity. In a recent webinar, Pharmatest — a contract...

Read More

Evaluating IO Bispecifics with PBMC-Humanized Mice

Humanized mice engrafted with human peripheral blood mononuclear cells (PBMCs) have become the preclinical workhorses for evaluating bispecific antibodies and other multi-specific, T cell-engaging cancer immunotherapies. PBMC-engrafted models, such as huPBMC-NOG are favored for their relative speed, versatility, affordability, and high level of translational relevance. Key to the effective application of PBMC-engrafted models is an understanding of their strengths and limitations. This article will highlight these strengths...

Read More

Improved Safety in CAR T Cell Therapy

The fight against cancer has recently improved by enlisting the patient's immune system to battle tumor cells. Administering checkpoint inhibitors, for example, can stop molecules such as PD-1 from interfering with T cell activity and allow T cells to attack cancer cells. Keytruda® (Merck) and Opdivo® (BMS) are two well-known checkpoint inhibitors that have improved treatment of certain cancer types. Checkpoint inhibitors work indirectly. CAR T cells...

Read More

New PBMC-humanized Mice Support Efficient NK-cell Engraftment

Favored for their relative speed, versatility, and translational relevance, humanized mice engrafted with human peripheral blood mononuclear cells (PBMCs) are the go-to preclinical models for evaluating T-cell-dependent immunotherapies. However, lacking important human cytokine signals, huPBMC-NOG and other PBMC models fail to support engraftment of important human immune cell subtypes, such as natural killer (NK) cells. This limits their utility for many studies. Recent work from Taconic Biosciences...

Read More

Webinar Q&A — Next Generation Humanized Mice in IO

The preclinical research community responded enthusiastically to Dr. Paul Volden's recent webinar, Next Generation Humanized Mice in Immuno-Oncology, the second webinar in a two-part series on humanized mice for preclinical immuno-oncology (IO). Several questions had to be cut from the presentation for time and are presented here, in full. Preclinical Immuno-Oncology Q&A Dr. Paul Volden (PV): The number of cells obtained from individual hematopoietic stem cell (HSC)...

Read More

Webinar Q&A — Humanized Mice in Preclinical Immuno-Oncology

Dr. Paul Volden recently presented a webinar on humanized mice in preclinical immuno-oncology research. Many of the questions you submitted to his Q&A session went unanswered due to time constraints, so here's the full Q&A. General Immuno-Oncology Questions Dr. Paul Volden (PV): I would not recommend commercially available humanized models for most cancer vaccine studies. To get sufficient vaccine response, you need interaction between antigen presenting cells...

Read More

New Options for IO Efficacy Testing

Structure of EMD Serono's bifunctional immune-oncology therapeutic M7824, from Lan et al.1 While new cancer immunotherapies offer fresh hope, not all patients respond to the currently available treatments. The race is on to identify efficacious combination therapies and next generation therapeutics, but preclinical efficacy testing is often hampered by immunogenicity in animal models. B cell-deficient animal models permit efficacy testing of immuno-oncology (IO) therapeutics when anti-drug antibodies...

Read More

Humanized Mice in Safety and Toxicity Testing

Humanized mice are invaluable tools for studying the function of the human immune system in an in vivo context, with applications for studying infectious disease, immuno-oncology, and immunology. Recently, Ryoji Ito and colleagues at the Central Institute for Experimental Animals in Japan demonstrated their efficacy in assessing the safety of chemotherapeutic drug candidates1. Humanized Mice and Myelotoxicity Testing Myelotoxicity is a common treatment-related adverse effect for antineoplastic...

Read More

Video: Mouse Models Used to Study Immuno-oncology

Taconic Biosciences' Dr. Philip Dubé discusses mouse models used to study immuno-oncology in this video excerpt from the webinar, "Advanced Toolkit For Syngeneic Tumor Modeling in Mice". There are essentially two types of models used in pre-clinical immuno-oncology research: Syngeneic models — a mouse tumor is implanted into a genetically identical and immuno-competent host Humanized models — severely immuno-deficient mice are implanted with both a human immune...

Read More

Seminar: Humanized Mice in Preclinical Bone Metastasis Studies

All are welcome to Biocom's continuing education seminar on the use of humanized mice in immuno-oncology and bone metastasis studies on April 12, 2018 at Larkspur Landing. Immuno-Oncology Seminar BioCom will hold an in-person continuing education seminar to explore new study design options in immuno-oncology supported by novel humanized mouse models, including a case study on how one particular humanized mouse could be used to study cancer...

Read More